-+ 0.00%
-+ 0.00%
-+ 0.00%

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

Barchart·10/20/2026 09:09:00
Listen to the news

EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU patients.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.